- Home
- STSS vs THAR Comparison
STSS vs THAR Comparison
Compare STSS & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- THAR
- Stock Information
- Founded
- STSS 2017
- THAR 2017
- Country
- STSS United States
- THAR United States
- Employees
- STSS N/A
- THAR N/A
- Industry
- STSS Medical/Dental Instruments
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- THAR Health Care
- Exchange
- STSS Nasdaq
- THAR Nasdaq
- Market Cap
- STSS 5.1M
- THAR 5.5M
- IPO Year
- STSS 2022
- THAR 2022
- Fundamental
- Price
- STSS $7.36
- THAR $4.72
- Analyst Decision
- STSS
- THAR Strong Buy
- Analyst Count
- STSS 0
- THAR 1
- Target Price
- STSS N/A
- THAR $17.00
- AVG Volume (30 Days)
- STSS 90.2K
- THAR 22.9M
- Earning Date
- STSS 08-13-2025
- THAR 08-14-2025
- Dividend Yield
- STSS N/A
- THAR N/A
- EPS Growth
- STSS N/A
- THAR N/A
- EPS
- STSS N/A
- THAR N/A
- Revenue
- STSS $222,722.00
- THAR N/A
- Revenue This Year
- STSS N/A
- THAR N/A
- Revenue Next Year
- STSS N/A
- THAR N/A
- P/E Ratio
- STSS N/A
- THAR N/A
- Revenue Growth
- STSS N/A
- THAR N/A
- 52 Week Low
- STSS $3.36
- THAR $0.95
- 52 Week High
- STSS $2,145.00
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- STSS 67.00
- THAR 83.95
- Support Level
- STSS $4.54
- THAR $1.08
- Resistance Level
- STSS $5.95
- THAR $6.09
- Average True Range (ATR)
- STSS 0.74
- THAR 0.52
- MACD
- STSS 0.18
- THAR 0.40
- Stochastic Oscillator
- STSS 96.92
- THAR 72.65
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.